MX2016010973A - Compuestos de aminocarbonilcarbamato. - Google Patents

Compuestos de aminocarbonilcarbamato.

Info

Publication number
MX2016010973A
MX2016010973A MX2016010973A MX2016010973A MX2016010973A MX 2016010973 A MX2016010973 A MX 2016010973A MX 2016010973 A MX2016010973 A MX 2016010973A MX 2016010973 A MX2016010973 A MX 2016010973A MX 2016010973 A MX2016010973 A MX 2016010973A
Authority
MX
Mexico
Prior art keywords
aminocarbonylcarbamate
compounds
aminocarbonylcarbamate compounds
compound
formula
Prior art date
Application number
MX2016010973A
Other languages
English (en)
Inventor
Soon Kang Young
Yong Chung Jin
Young Maeng Cheol
Ju Yi Han
Ho Lee Ki
Heo Joon
Hee Chae Eun
Jin Shin Yu
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2016010973A publication Critical patent/MX2016010973A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/58—Y being a hetero atom
    • C07C275/60—Y being an oxygen atom, e.g. allophanic acids

Abstract

La presente divulgación brinda un compuesto representado por la Fórmula (I), y una sal farmacéuticamente aceptable que es eficaz como un inhibidor de la recaptación de dopamina, y un método que usa el compuesto: (ver Fórmula) en el cual X es, independientemente, halo, alquilo, alcoxi o nitro; m es 0, 1, 2, 3 ó 4; n es 1 ó 2; R1 y R2 son, independientemente, H- o alquilo; R3 es H-, alquilo o aralquilo; y R4 es H- o arilo.
MX2016010973A 2014-02-28 2015-02-27 Compuestos de aminocarbonilcarbamato. MX2016010973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946142P 2014-02-28 2014-02-28
PCT/KR2015/001915 WO2015130121A1 (en) 2014-02-28 2015-02-27 Aminocarbonylcarbamate compounds

Publications (1)

Publication Number Publication Date
MX2016010973A true MX2016010973A (es) 2016-11-29

Family

ID=54006446

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010973A MX2016010973A (es) 2014-02-28 2015-02-27 Compuestos de aminocarbonilcarbamato.
MX2020003020A MX2020003020A (es) 2014-02-28 2015-02-27 Compuestos de aminocarbonilcarbamato.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003020A MX2020003020A (es) 2014-02-28 2015-02-27 Compuestos de aminocarbonilcarbamato.

Country Status (15)

Country Link
US (4) US9403761B2 (es)
EP (2) EP3110792B1 (es)
JP (2) JP6452731B2 (es)
KR (2) KR102309903B1 (es)
CN (2) CN106458866B (es)
AR (1) AR099581A1 (es)
AU (2) AU2015223579B2 (es)
CA (1) CA2939835C (es)
CL (1) CL2016002165A1 (es)
ES (1) ES2759312T3 (es)
MX (2) MX2016010973A (es)
PL (1) PL3110792T3 (es)
RU (1) RU2688673C2 (es)
TW (2) TWI655179B (es)
WO (1) WO2015130121A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) * 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
SG11201901998WA (en) * 2016-09-06 2019-04-29 Jazz Pharmaceuticals International Iii Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
KR102616545B1 (ko) * 2016-10-06 2023-12-26 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라닌올 화합물 및 이의 용도
CA3065522A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CN111153863A (zh) * 2019-12-13 2020-05-15 浙江工业大学 一种合成动物用抗球虫药物妥曲珠利的方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077289A (en) * 1989-11-30 1991-12-31 Hoechst Roussel Pharmaceuticals Inc. Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine
EP0665226A1 (en) * 1992-10-28 1995-08-02 Toyama Chemical Co., Ltd. Novel 1,2-benzisoxazole derivative or salt thereof, and brain protective agent comprising the same
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO2004111006A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Para-subtituted phenyl carbamates as inhibitors of hormone sensitive lipase
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
JP4676961B2 (ja) * 2003-10-21 2011-04-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害し、薬理活性物質を放出するカルバモイルエステル類
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
CN101631770A (zh) * 2007-02-02 2010-01-20 科露西德医药品公司 抑制胆碱酯酶的化合物
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
PL2496228T3 (pl) * 2009-11-06 2014-06-30 Sk Biopharmaceuticals Co Ltd Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
TW201919605A (zh) * 2013-07-18 2019-06-01 南韓商愛思開生物製藥股份有限公司 肥胖之治療
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物

Also Published As

Publication number Publication date
US9403761B2 (en) 2016-08-02
JP6452731B2 (ja) 2019-01-16
ES2759312T3 (es) 2020-05-08
TW201920086A (zh) 2019-06-01
CN109627186B (zh) 2021-10-29
JP6595078B2 (ja) 2019-10-23
RU2016136193A (ru) 2018-03-30
CN109627186A (zh) 2019-04-16
EP3587394A1 (en) 2020-01-01
KR20160126988A (ko) 2016-11-02
RU2019113158A (ru) 2019-06-25
MX2020003020A (es) 2021-11-11
AU2015223579A1 (en) 2016-08-25
EP3110792B1 (en) 2019-09-04
EP3587394B1 (en) 2023-11-01
RU2016136193A3 (es) 2018-10-29
US20160303067A1 (en) 2016-10-20
KR20210124520A (ko) 2021-10-14
TWI655179B (zh) 2019-04-01
EP3110792A4 (en) 2017-09-27
US9833432B2 (en) 2017-12-05
AU2019236666B2 (en) 2021-03-25
JP2019059764A (ja) 2019-04-18
AU2015223579B2 (en) 2019-06-27
US20180085337A1 (en) 2018-03-29
US10314808B2 (en) 2019-06-11
KR102487051B1 (ko) 2023-01-09
CN106458866B (zh) 2018-12-07
CL2016002165A1 (es) 2017-06-09
KR102309903B1 (ko) 2021-10-06
US20150246874A1 (en) 2015-09-03
JP2017512211A (ja) 2017-05-18
RU2688673C2 (ru) 2019-05-22
TWI698415B (zh) 2020-07-11
WO2015130121A1 (en) 2015-09-03
CA2939835C (en) 2022-11-01
EP3110792A1 (en) 2017-01-04
PL3110792T3 (pl) 2020-02-28
CA2939835A1 (en) 2015-09-03
US20190247356A1 (en) 2019-08-15
US10485781B2 (en) 2019-11-26
TW201623224A (zh) 2016-07-01
AR099581A1 (es) 2016-08-03
CN106458866A (zh) 2017-02-22
AU2019236666A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
MX2020003020A (es) Compuestos de aminocarbonilcarbamato.
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
PH12016500169A1 (en) Polymorph of syk inhibitors
PH12017501523A1 (en) Selective bace1 inhibitors
TW201613853A (en) Synthesis of polycyclic-carbamoylpyridone compounds
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12018500903A1 (en) Pyranodipyridine compound
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
IN2014MU01192A (es)
IN2014MU00195A (es)
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
IN2014MU00194A (es)
IN2014MU01196A (es)
IN2014MU00072A (es)
UA107885U (uk) Застосування вінборону для профілактики гастропатії, індукованої ібупрофеном
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
IN2014MU00858A (es)
IN2014MU01195A (es)
IN2014MU00070A (es)

Legal Events

Date Code Title Description
FG Grant or registration